Vasudev Jaiprakash Bailey - 23 Oct 2025 Form 4 Insider Report for Rani Therapeutics Holdings, Inc. (RANI)

Reporting relationship: Director
Issuer ticker: RANI
Reported as of: 23 Oct 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Oct 2025, 16:31:44 UTC
Next SEC filing: 01 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Svai Sanford, Attorney-in-Fact

Key filing fact

Vasudev Jaiprakash Bailey filed Form 4 for Rani Therapeutics Holdings, Inc. (RANI) on 30 Oct 2025.

Key facts

This page summarizes Vasudev Jaiprakash Bailey's Form 4 filing for Rani Therapeutics Holdings, Inc. (RANI).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Oct 2025, 16:31.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002094741 Primary reporting owner

Bailey Vasudev Jaiprakash

Relationship: Director
Address: C/O RANI THERAPEUTICS LLC, 2051 RINGWOOD AVE., SAN JOSE
Signature: /s/ Svai Sanford, Attorney-in-Fact
Signature date: 30 Oct 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RANI transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +100,000
Change %
Price: $0.000000
Shares after: 100,000
Date: 23 Oct 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 100,000
Exercise price: $2.09
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares subject to this option will vest over a three-year period, with one-third of the shares subject to the option vesting on October 23, 2026, and one thirty-sixth of the shares subject to the option vesting each month thereafter, subject to the Reporting Person's continuous service with the Company through each vesting date.